How ImmunoGen Trounced Analysts’ Q4 Revenue and Earnings Estimates

1 min read

If you liked the gains generated by ImmunoGen (NASDAQ: IMGN) in 2020, you’re loving the stock in 2021. So far this year, the biotech’s shares have soared 32%. And that momentum is now likely to build even more.

ImmunoGen announced its fourth-quarter results before the market opened on Friday. Investors liked what they saw. Here are the highlights of ImmunoGen’s Q4 update.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Why Fisker Stock Is Higher Today

Next Story

Why CarGurus’ Stock Is Lower Today

Latest from Blog